Coordination Compounds in Diagnostic Imaging and Theranostics: Emerging Trends in Biomedical Applications

Introduction

Early and accurate diagnosis plays a critical role in the successful management of numerous diseases, particularly cancer, cardiovascular disorders, neurological diseases, and infectious conditions. Conventional diagnostic techniques often provide limited molecular information and may fail to detect diseases during their early stages. Simultaneously, traditional therapeutic approaches frequently suffer from poor selectivity, systemic toxicity, and inadequate monitoring of treatment response. These limitations have stimulated the development of advanced biomedical technologies capable of integrating diagnosis and therapy into a single platform. Coordination compounds have become increasingly important in biomedical imaging because of the unique coordination chemistry of transition metals and lanthanides [1]. Their adjustable oxidation states, variable coordination geometries, favorable magnetic properties, and radiochemical characteristics make them ideal candidates for developing highly sensitive imaging probes and targeted therapeutic agents. Since the introduction of gadolinium-based contrast agents for magnetic resonance imaging and technetium-99m complexes for nuclear medicine, coordination chemistry has become an essential component of modern diagnostic imaging. The emergence of theranostics, which combines therapeutic and diagnostic functions within a single molecular system, represents one of the most significant advances in personalized medicine. Coordination compounds serve as excellent theranostic agents because they can simultaneously deliver drugs, generate diagnostic signals, monitor treatment response, and selectively target diseased tissues. Metal complexes incorporating radioactive isotopes, fluorescent probes, nanoparticles, and targeting ligands have demonstrated remarkable potential for improving disease detection while minimizing toxicity to healthy tissues[2] . Recent advances in nanotechnology, molecular imaging, computational chemistry, and targeted drug delivery have further accelerated the development of multifunctional coordination compounds with enhanced imaging sensitivity, therapeutic efficacy, and biological safety. These innovations have opened new opportunities for precision medicine by enabling individualized diagnosis, targeted treatment, and real-time monitoring of therapeutic outcomes. This review summarizes recent developments in coordination compounds used for diagnostic imaging and theranostic applications, emphasizing their chemistry, classification, imaging mechanisms, biomedical applications, current limitations, and future research directions.

2. Fundamentals of Coordination Chemistry in Biomedical Imaging

Coordination compounds consist of a central metal ion surrounded by ligands that donate electron pairs through coordinate covalent bonds. The metal center determines the magnetic, radioactive, optical, and electronic properties of the complex, whereas the ligands influence stability, solubility, biodistribution, pharmacokinetics, and biological specificity. Careful selection of both the metal ion and ligand structure enables the development of imaging agents with high sensitivity, target specificity, and minimal toxicity. In diagnostic imaging, coordination compounds function by altering magnetic relaxation, emitting gamma rays, positrons, or fluorescent signals, or enhancing contrast between healthy and diseased tissues. Lanthanide complexes such as gadolinium exhibit strong paramagnetic properties suitable for MRI contrast enhancement, whereas radiometal complexes containing technetium, gallium, copper, zirconium, and indium are widely employed in nuclear imaging techniques including PET and SPECT [3]. Fluorescent metal complexes based on ruthenium, iridium, and europium provide high photostability and excellent optical properties for cellular imaging and molecular diagnostics. Modern ligand engineering has further improved imaging performance by incorporating peptides, antibodies, carbohydrates, folic acid, aptamers, and small biomolecules that selectively recognize disease-associated biomarkers. This targeted approach significantly enhances imaging sensitivity while reducing nonspecific accumulation in healthy tissues.

3. Classification of Coordination Compounds Used in Diagnostic Imaging

Coordination compounds used in biomedical imaging are generally classified according to the imaging modality and the metal ion employed. Gadolinium-based complexes remain the most widely used contrast agents for magnetic resonance imaging because of their excellent paramagnetic properties and ability to shorten proton relaxation times, thereby improving image contrast. Common gadolinium chelates include gadopentetate dimeglumine, gadoterate meglumine, gadobutrol, and gadoteridol. Radiometal coordination compounds form the foundation of nuclear medicine imaging. Technetium-99m complexes are extensively utilized in SPECT imaging owing to their favorable half-life, gamma-ray emission, and wide availability. Gallium-68, copper-64, zirconium-89, indium-111, and lutetium-177 coordination compounds have become increasingly important for PET imaging, targeted radionuclide therapy, and theranostic applications. Optical imaging agents include ruthenium, iridium, europium, terbium, and platinum coordination complexes that exhibit excellent fluorescence properties, long emission lifetimes, and high photostability [4]. These compounds are widely applied in fluorescence microscopy, cellular imaging, biosensing, and molecular diagnostics. Nanotechnology has further expanded this classification by integrating coordination compounds into nanoparticles, liposomes, dendrimers, metal-organic frameworks (MOFs), polymeric nanocarriers, and hybrid nanomaterials. These multifunctional systems combine imaging, drug delivery, and therapeutic functions within a single platform, significantly enhancing biomedical performance.

4. Coordination Compounds in Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Single-Photon Emission Computed Tomography (SPECT)

Coordination compounds have become indispensable components of modern biomedical imaging because they significantly improve the sensitivity, specificity, and diagnostic accuracy of non-invasive imaging techniques. Among these modalities, magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT) represent the most widely used clinical imaging technologies. The unique magnetic, radioactive, and electronic properties of metal coordination complexes enable enhanced visualization of anatomical structures, physiological functions, and molecular biomarkers associated with various diseases. Gadolinium-based coordination compounds remain the gold standard contrast agents for MRI. Gadolinium(III) possesses seven unpaired electrons, making it highly paramagnetic and capable of shortening proton relaxation times in surrounding tissues. Chelating ligands such as DTPA and DOTA stabilize gadolinium ions, reducing toxicity while improving circulation time and tissue distribution. MRI contrast agents are extensively used in the diagnosis of neurological disorders, cardiovascular diseases, musculoskeletal abnormalities, liver diseases, and solid tumors. PET imaging employs positron-emitting radionuclides coordinated to biologically active ligands [5]. Gallium-68, Copper-64, Zirconium-89, and Scandium-44 complexes have demonstrated remarkable success in molecular imaging because they provide excellent sensitivity and quantitative assessment of disease progression. These radiometal complexes are frequently conjugated with antibodies, peptides, or receptor-specific ligands to selectively accumulate in tumor tissues, thereby enabling early cancer detection and monitoring of therapeutic response. Technetium-99m coordination compounds dominate SPECT imaging because of their favorable nuclear properties, short half-life, low radiation burden, and widespread availability. Technetium complexes are routinely employed for myocardial perfusion imaging, bone scanning, renal imaging, thyroid evaluation, pulmonary imaging, and infection localization. Indium-111 and Lutetium-177 coordination compounds further expand nuclear imaging capabilities, particularly in targeted radionuclide therapy and personalized medicine. Recent developments have focused on multimodal imaging agents capable of integrating MRI, PET, SPECT, fluorescence imaging, and computed tomography within a single coordination complex. Such multifunctional systems improve diagnostic precision while reducing the number of separate imaging procedures required for comprehensive disease evaluation.

5. Theranostic Applications of Coordination Compounds

Theranostics is an emerging biomedical approach that integrates diagnostic imaging and targeted therapy into a single molecular platform, enabling simultaneous disease detection, treatment, and monitoring. Coordination compounds are particularly suitable for theranostic applications because their structural versatility allows the incorporation of imaging agents, therapeutic drugs, targeting ligands, and responsive delivery systems within one multifunctional complex. Cancer remains the principal focus of coordination compound-based theranostics. Radiometal complexes incorporating Lutetium-177, Copper-64, Gallium-68, Actinium-225, and Yttrium-90 have demonstrated excellent potential for simultaneous tumor imaging and radionuclide therapy. These compounds selectively accumulate in malignant tissues through receptor-mediated targeting while providing real-time visualization of drug distribution and therapeutic efficacy. Several coordination compounds also function as photosensitizers in photodynamic therapy (PDT). Ruthenium and iridium complexes absorb visible light and generate reactive oxygen species upon irradiation, causing localized destruction of tumor cells while minimizing damage to surrounding healthy tissues. Similarly, photothermal therapy utilizes metal-containing nanocomposites that convert near-infrared light into heat, inducing selective tumor ablation. Coordination compounds have further been incorporated into targeted chemotherapy systems. Platinum and ruthenium complexes encapsulated within nanoparticles, liposomes, dendrimers, and metal-organic frameworks enable controlled drug release, prolonged circulation, enhanced tumor accumulation, and reduced systemic toxicity [6]. These delivery platforms improve therapeutic outcomes while minimizing adverse effects commonly associated with conventional chemotherapy. Beyond oncology, theranostic coordination compounds have shown promising applications in neurological disorders, cardiovascular diseases, inflammatory diseases, bacterial infections, and neurodegenerative conditions. Their ability to combine diagnosis with personalized treatment makes them valuable tools in precision medicine.

6. Nanotechnology-Based Coordination Compounds in Biomedical Applications

Nanotechnology has revolutionized coordination compound research by improving the stability, biocompatibility, pharmacokinetics, and targeting efficiency of imaging agents. Nanocarriers protect coordination compounds from premature degradation while promoting selective accumulation in diseased tissues through passive and active targeting mechanisms. Numerous nanosystems, including liposomes, polymeric nanoparticles, dendrimers, silica nanoparticles, gold nanoparticles, magnetic nanoparticles, and metal-organic frameworks (MOFs), have been successfully employed as carriers for coordination compounds. These systems facilitate controlled drug release, improved circulation time, reduced systemic toxicity, and enhanced imaging sensitivity. Surface functionalization with antibodies, peptides, aptamers, folic acid, carbohydrates, and receptor-specific ligands further increases target specificity toward cancer cells or diseased tissues. Stimuli-responsive nanocarriers capable of releasing therapeutic agents in response to pH, temperature, enzymes, or redox conditions provide additional control over drug delivery while reducing off-target effects [7]. The integration of artificial intelligence, molecular imaging, computational chemistry, and nanotechnology is expected to accelerate the development of highly personalized theranostic systems capable of early diagnosis, real-time monitoring, and individualized treatment planning.

7. Challenges and Future Perspectives

Despite remarkable progress, several challenges remain before coordination compound-based imaging agents and theranostic systems achieve widespread clinical application. Safety remains a major concern, particularly regarding long-term retention of certain metal ions and potential toxicity associated with repeated administration. Although chelating ligands significantly reduce metal toxicity, continuous efforts are required to develop highly stable complexes with improved biological clearance. Another important challenge involves achieving optimal target specificity while minimizing nonspecific uptake in healthy tissues. Advances in ligand engineering, biomarker identification, molecular targeting, and computational drug design are expected to improve the selectivity of future imaging agents [8-11]. Standardization of synthesis protocols, quality control, regulatory approval processes, and large-scale manufacturing also remain essential for successful clinical translation. Future research will likely emphasize biodegradable coordination compounds, multimodal imaging platforms, artificial intelligence-assisted image analysis, personalized theranostics, and smart nanocarriers capable of responding to disease-specific microenvironments. Integration of coordination chemistry with molecular biology, genomics, proteomics, and precision medicine will further expand the diagnostic and therapeutic capabilities of these multifunctional systems.

8. Conclusion

Coordination compounds have become fundamental components of modern diagnostic imaging and represent one of the most rapidly advancing areas of biomedical research. Their unique magnetic, radioactive, optical, and coordination properties have enabled the development of highly sensitive imaging agents for MRI, PET, SPECT, fluorescence imaging, and multimodal diagnostic platforms. Gadolinium, technetium, gallium, copper, zirconium, ruthenium, iridium, and other metal coordination complexes continue to play essential roles in disease detection, molecular imaging, and clinical diagnosis. The emergence of theranostics has further expanded the biomedical significance of coordination compounds by integrating diagnosis and therapy within a single multifunctional platform. These systems facilitate targeted drug delivery, radionuclide therapy, photodynamic therapy, photothermal therapy, and real-time monitoring of treatment response, thereby improving therapeutic precision while minimizing systemic toxicity. Advances in nanotechnology, ligand engineering, molecular targeting, and bioinorganic chemistry have substantially enhanced the performance of coordination compound-based imaging agents and accelerated their translation toward precision medicine. Nevertheless, important challenges related to long-term safety, metal toxicity, pharmacokinetics, target specificity, and regulatory approval remain to be addressed. Continued interdisciplinary research involving coordination chemistry, nanomedicine, molecular imaging, computational modeling, artificial intelligence, and clinical medicine will be essential for developing safer, more effective, and patient-specific theranostic systems, coordination compounds are expected to play an increasingly important role in next-generation biomedical imaging and personalized healthcare.

References

1. Imran, M., Ramzan, M., Qureshi, A. K., Khan, M. A., & Tariq, M. (2018). Emerging applications of porphyrins and metalloporphyrins in biomedicine and diagnostic magnetic resonance imaging. Biosensors, 8(4), 95.
2. Li, X., Cai, Z., Jiang, L. P., He, Z., & Zhu, J. J. (2019). Metal–ligand coordination nanomaterials for biomedical imaging. Bioconjugate Chemistry, 31(2), 332-339.
3. Gomes Marin, J. F., Nunes, R. F., Coutinho, A. M., Zaniboni, E. C., Costa, L. B., Barbosa, F. G.,  & Buchpiguel, C. A. (2020). Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. Radiographics, 40(6), 1715-1740.
4. Robertson, A. G., & Rendina, L. M. (2021). Gadolinium theranostics for the diagnosis and treatment of cancer. Chemical Society Reviews, 50(7), 4231-4244.
5. Pöthig, A., & Casini, A. (2019). Recent developments of supramolecular metal-based structures for applications in cancer therapy and imaging. Theranostics, 9(11), 3150.
6. Patra, C. R. (2016). Prussian blue nanoparticles and their analogues for application to cancer theranostics. Nanomedicine, 11(6), 569-572.
7. Tuo, W., Xu, Y., Fan, Y., Li, J., Qiu, M., Xiong, X.,  & Sun, Y. (2021). Biomedical applications of Pt (II) metallacycle/metallacage-based agents: From mono-chemotherapy to versatile imaging contrasts and theranostic platforms. Coordination Chemistry Reviews, 443, 214017.
8. Jadvar, H., Chen, X., Cai, W., & Mahmood, U. (2018). Radiotheranostics in cancer diagnosis and management. Radiology, 286(2), 388-400.
9. Zhang, H., Kang, L., Zou, Q., Xin, X., & Yan, X. (2019). Coordination-assembled supramolecular nanoplatforms: structural modulation and theranostic applications. Current opinion in biotechnology, 58, 45-52.
10. Beg, Sarwar, Mahfoozur Rahman, Atul Jain, Sumant Saini, Patrick Midoux, Chantal Pichon, Farhan Jalees Ahmad, and Sohail Akhter. “Nanoporous metal organic frameworks as hybrid polymer–metal composites for drug delivery and biomedical applications.” Drug Discovery Today 22, no. 4 (2017): 625-637.
11. Chedid, G., & Yassin, A. (2018). Recent trends in covalent and metal organic frameworks for biomedical applications. Nanomaterials, 8(11), 916.